ALK and non-small cell squamous lung carcinoma: In the same year, it was designated by the FDA as a breakthrough therapy for metastatic squamous and non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression which continued to progress on or after platinum-based chemotherapy or an FDA-approved EGFR or ALK targeted agent (Dang et al. 2016).